CRXM WACC - Weighted Average Cost of Capital
The WACC of Gene Biotherapeutics Inc (CRXM) is 3.9%.
| Range | Selected | |
| Cost of equity | 850.3% - 3760.7% | 2305.5% |
| Tax rate | 26.2% - 27.0% | 26.6% |
| Cost of debt | 5.0% - 5.0% | 5% |
| WACC | 3.8% - 4.1% | 3.9% |
| Category | Low | High |
| Long-term bond rate | 3.9% | 4.4% |
| Equity market risk premium | 4.6% | 5.6% |
| Adjusted beta | 184 | 670.69 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 850.3% | 3760.7% |
| Tax rate | 26.2% | 27.0% |
| Debt/Equity ratio | 9078.08 | 9078.08 |
| Cost of debt | 5.0% | 5.0% |
| After-tax WACC | 3.8% | 4.1% |
| Selected WACC | 3.9% | |
| Debt/Equity | Unlevered | |||
| Peers | Company Name | ratio | Beta | beta |
| CRXM | Gene Biotherapeutics Inc | 9078.08 | 26.31 | 0 |
| Low | High | |
| Unlevered beta | 0 | 0 |
| Relevered beta | 274.13 | 1000.54 |
| Adjusted relevered beta | 184 | 670.69 |
CRXM's CAPM model and how its cost of Equity is calculated
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for CRXM:
cost_of_equity (2,305.50%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (184) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.